

Roberta Gualtierotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/701262/publications.pdf>

Version: 2024-02-01

97
papers

4,212
citations

249298

26
h-index

139680

61
g-index

104
all docs

104
docs citations

104
times ranked

10390
citing authors

#	ARTICLE	IF	CITATIONS
1	Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy. <i>Pain and Therapy</i> , 2022, 11, 1-15.	1.5	4
2	Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19 hospitalized patients. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13753.	1.7	13
3	Ultrasound Features of Adhesive Capsulitis. <i>Rheumatology and Therapy</i> , 2022, 9, 481-495.	1.1	12
4	A Response to: Letter to the Editor Regarding Ultrasound Features of Adhesive Capsulitis. <i>Rheumatology and Therapy</i> , 2022, 9, 1225-1228.	1.1	1
5	The ADAMTS13 von Willebrand factor axis in COVID-19 patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 513-521.	1.9	176
6	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. <i>Journal of Autoimmunity</i> , 2021, 116, 102560.	3.0	127
7	Hemostatic alterations in COVID-19. <i>Haematologica</i> , 2021, 106, 1472-1475.	1.7	34
8	Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem. <i>Advances in Therapy</i> , 2021, 38, 2709-2716.	1.3	2
9	Hemophilic arthropathy: Current knowledge and future perspectives. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2112-2121.	1.9	84
10	No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2. <i>Thrombosis Update</i> , 2021, 4, 100059.	0.4	6
11	Which Level of Emicizumab Is Necessary for a Good Hemostasis?. <i>Blood</i> , 2021, 138, 4247-4247.	0.6	0
12	Real-World Experience with Emicizumab Prophylaxis in the Milan Cohort: A Single-Center Experience. <i>Blood</i> , 2021, 138, 1038-1038.	0.6	0
13	Transmembrane Protein TMEM230, a Target of Glioblastoma Therapy. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 703431.	1.8	1
14	Anti-Emicizumab Antibodies Do Not Cross-React with Mim8 in Vitro. <i>Blood</i> , 2021, 138, 3193-3193.	0.6	0
15	Management of Painful Shoulder Arthroplasty: A Narrative Review. <i>Pain and Therapy</i> , 2020, 9, 427-439.	1.5	6
16	Anti-atherogenic Modification of Serum Lipoprotein Function in Patients with Rheumatoid Arthritis after Tocilizumab Treatment, a Pilot Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2157.	1.0	18
17	Inflammatory interactions between degenerated intervertebral discs and microglia: Implication of sphingosine-1-phosphate signaling. <i>Journal of Orthopaedic Research</i> , 2020, 39, 1479-1495.	1.2	6
18	The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians. <i>Journal of Clinical Medicine</i> , 2020, 9, 3379.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Early Phases of COVID-19 Are Characterized by a Reduction in Lymphocyte Populations and the Presence of Atypical Monocytes. <i>Frontiers in Immunology</i> , 2020, 11, 560330.	2.2	47
20	Complement activation in patients with COVID-19: A novel therapeutic target. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 215-217.	1.5	210
21	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	13.9	1,548
22	Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6 ⁺ B helper T cells in systemic lupus erythematosus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7305-7316.	3.3	35
23	Hereditary Deficiency of the Second Component of Complement: Early Diagnosis and 21-Year Follow-Up of a Family. <i>Medicina (Lithuania)</i> , 2020, 56, 120.	0.8	0
24	Acute Portal Vein Thrombosis in SARS-CoV-2 Infection: A Case Report. <i>American Journal of Gastroenterology</i> , 2020, 115, 1140-1142.	0.2	33
25	COVID-19 Network: the response of an Italian Reference Institute to research challenges about a new pandemia. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1576-1578.	2.8	10
26	Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2019, 36, 3494-3502.	1.3	13
27	Identification of a Shared Microbiomic and Metabolomic Profile in Systemic Autoimmune Diseases. <i>Journal of Clinical Medicine</i> , 2019, 8, 1291.	1.0	37
28	Fibromyalgia and Shoulder Surgery: A Systematic Review and a Critical Appraisal of the Literature. <i>Journal of Clinical Medicine</i> , 2019, 8, 1518.	1.0	6
29	Hormones and Autoimmunity. , 2019, , 181-190.		0
30	Personalized Medicine in Autoimmunity. , 2019, , 619-624.		0
31	Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report. <i>Journal of Clinical Medicine</i> , 2019, 8, 398.	1.0	7
32	Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases. <i>Journal of Clinical Medicine</i> , 2019, 8, 21.	1.0	28
33	P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , 2019, 216, 317-336.	4.2	83
34	IFI16 and Anti-IFI16 as Novel Biomarkers for Sjogren's Syndrome: Preliminary Data. <i>Proceedings (mdpi)</i> , 2019, 35, .	0.2	0
35	The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts. <i>Medicine (United States)</i> , 2018, 97, e0370.	0.4	4
36	Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview. <i>Advances in Therapy</i> , 2018, 35, 439-456.	1.3	35

#	ARTICLE	IF	CITATIONS
37	Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 269-281.	2.9	16
38	Neutrophilic Dermatoses and Joint Disorders. , 2018, , 247-258.		0
39	Total Joint Arthroplasty in Patients with Inflammatory Rheumatic Diseases. <i>Advances in Therapy</i> , 2018, 35, 1133-1139.	1.3	10
40	Vitamin D and Anti-Phospholipid Antibody Syndrome: A Comprehensive Review. <i>Open Rheumatology Journal</i> , 2018, 12, 248-260.	0.1	5
41	Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 643-647.	0.4	18
42	Detection of early endothelial damage in patients with Raynaud's phenomenon. <i>Microvascular Research</i> , 2017, 113, 22-28.	1.1	19
43	Modulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids. <i>Advances in Therapy</i> , 2017, 34, 396-420.	1.3	47
44	Understanding cardiovascular risk in rheumatoid arthritis: Still a long way to go. <i>Atherosclerosis</i> , 2017, 256, 123-124.	0.4	8
45	SAT0655â€¦Early endothelial damage in patients with raynaud's phenomenon. , 2017, , .		0
46	Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2017, 4, 293-308.	1.1	17
47	THU0240â€¦Defective regulation by ATP-GATED ionotropic P2X7 receptor drives T follicular helper cell expansion in systemic lupus erythematosus. , 2017, , .		2
48	Inflammatory mediators and signalling pathways controlling intervertebral disc degeneration. <i>Histology and Histopathology</i> , 2017, 32, 523-542.	0.5	102
49	Smac127 Has Proapoptotic and Anti-Inflammatory Effects on Rheumatoid Arthritis Fibroblast-Like Synoviocytes. <i>Mediators of Inflammation</i> , 2016, 2016, 1-9.	1.4	6
50	Health-Related Quality of Life in Systemic Sclerosis: Feasibility and Construct Validity of Eq-5d. <i>Value in Health</i> , 2016, 19, A596.	0.1	0
51	The Adipose Mesenchymal Stem Cell Secretome Inhibits Inflammatory Responses of Microglia: Evidence for an Involvement of Sphingosine-1-Phosphate Signalling. <i>Stem Cells and Development</i> , 2016, 25, 1095-1107.	1.1	33
52	Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis. <i>Swiss Medical Weekly</i> , 2016, 146, w14394.	0.8	9
53	Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 451-8.	0.4	16
54	OPO221â€¦Nailfold Capillaroscopy Patterns in Adulthood are Similar in Patients with Juvenile and Adult-Onset Systemic Sclerosis: A Eustar Case-Control Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 154.3-155.	0.5	0

#	ARTICLE	IF	CITATIONS
55	AB1085â€¦Empirical Approach to Investigate Raynaud's Phenomenon: The Pearl Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1263.2-1263.	0.5	0
56	FRIO486â€¦Health-Related Quality of Life in Systemic Sclerosis as Measured by SF-36, EQ-5D and SF-6D: Comparison with a Primary Raynaud Phenomenon and a Selected Sample of Healthy Controls. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 604.2-604.	0.5	0
57	Uniphasic Blanching of the Fingers, Abnormal Capillaroscopy in Nonsymptomatic Digits, and Autoantibodies: Expanding Options to Increase the Level of Suspicion of Connective Tissue Diseases beyond the Classification of Raynaudâ€™s Phenomenon. <i>Journal of Immunology Research</i> , 2015, 2015, 1-7.	0.9	13
58	Sparing effect of hemiplegia on skin fibrosis and microvascular involvement: Reports of two cases of systemic sclerosis and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 597-601.	1.6	4
59	Mesenchymal stem cells: potential for therapy and treatment of chronic non-healing skin wounds. <i>Organogenesis</i> , 2015, 11, 183-206.	0.4	91
60	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	1.1	13
61	Gene Expression Profile Analysis of Human Mesenchymal Stem Cells from Herniated and Degenerated Intervertebral Discs Reveals Different Expression of Osteopontin. <i>Stem Cells and Development</i> , 2015, 24, 320-328.	1.1	13
62	Choroidal impairment and macular thinning in patients with systemic sclerosis: The acute study. <i>Microvascular Research</i> , 2015, 97, 31-36.	1.1	51
63	Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S55-60.	0.4	7
64	Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 307-315.	1.3	5
65	Choosing treatment options for patients with relapsed/refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 199-215.	1.1	5
66	Is it safe to withdraw etanercept in established rheumatoid arthritis after low disease activity achievement?. <i>Internal and Emergency Medicine</i> , 2014, 9, 223-224.	1.0	2
67	Rheumatoid Factors. , 2014, , 751-760.		1
68	Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1440-1448.	1.9	93
69	Autoantibodies to coagulation factors: From pathophysiology to diagnosis and therapy. <i>Autoimmunity Reviews</i> , 2014, 13, 40-48.	2.5	50
70	Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 940-941.	0.5	11
71	Tocilizumab Monotherapy in a Patient with Rheumatoid Arthritis and Iatrogenic Kaposi Sarcoma. <i>Clinical Drug Investigation</i> , 2014, 34, 159-161.	1.1	8
72	Authorsâ€™ Reply to Verdelli et al.: There Is No Knowledge Without Experience. <i>Clinical Drug Investigation</i> , 2014, 34, 439-439.	1.1	0

#	ARTICLE	IF	CITATIONS
73	AB1013â€¦Systemic Sclerosis and Myositis Extractable Nuclear Antigen (ENA) Analysis: Profile of A Cohort of Subjects with Isolated Raynaud's Phenomenon. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1135.3-1135.	0.5	0
74	Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1875-1884.	0.9	13
75	Pre-conceptional exposure to rituximab: comment on the article by Ojeda-Urbe et al.. <i>Clinical Rheumatology</i> , 2013, 32, 727-728.	1.0	5
76	Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2463-2473.	0.9	3
77	Cutting-Edge Issues in Coronary Disease and the Primary Antiphospholipid Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 44, 51-56.	2.9	21
78	Nailfold capillary patterns in healthy subjects: A real issue in capillaroscopy. <i>Microvascular Research</i> , 2013, 90, 90-95.	1.1	79
79	A systematic overview on the use and relevance of capillaroscopy in systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 1091-1097.	1.3	27
80	SAT0214â€¦Reliability and Validity of the Italian Version of the Ucla-Scleroderma Clinical Trial Consortium-Gastrointestinal Tract Instrument in Patients with Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A653.1-A653.	0.5	1
81	Rheumatoid Factors: Clinical Applications. <i>Disease Markers</i> , 2013, 35, 727-734.	0.6	211
82	Current and Emerging Treatment Options for Patients with Relapsed Myeloma. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S8014.	0.6	21
83	An overlooked cause of back pain and stiffness. <i>Rheumatology</i> , 2013, 52, 985.	0.9	1
84	FRI0403â€¦How early starts increased collagen synthesis in systemic sclerosis?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A510.1-A510.	0.5	0
85	SAT0401â€¦The nailfold capillary patterns in healthy subjects: A two center study. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 607.4-608.	0.5	0
86	AB0830â€¦Role of anti-IFI16 antibodies and NT-PROBNP as candidate biomarkers in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 686.3-686.	0.5	0
87	FRI0402â€¦Vascular changes in choroid plexus in patients with raynaudâ€™s phenomenon suspected secondary to a connective tissue disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A509.3-A509.	0.5	0
88	Rheumatoid Nodules Predating Seroconversion and Rheumatoid Arthritis: An Uncommon Case Report. <i>Journal of Clinical & Cellular Immunology</i> , 2013, 04, .	1.5	0
89	The Role of Ultrasonography in the Assessment of Skeletal Hand Involvement in Systemic Sclerosis. <i>Journal of Medical Ultrasound</i> , 2011, 19, 141-142.	0.2	1
90	Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis. <i>Current Vascular Pharmacology</i> , 2010, 8, 285-292.	0.8	30

#	ARTICLE	IF	CITATIONS
91	Updating on the pathogenesis of systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2010, 10, 3-7.	2.5	170
92	Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy. <i>Rheumatology</i> , 2010, 49, 797-805.	0.9	86
93	Hand impairment in systemic sclerosis: association of different hand indices with organ involvement. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 393-397.	0.6	11
94	Feasibility of Different Capillaroscopic Measures for Identifying Nailfold Microvascular Alterations. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 38, 289-295.	1.6	66
95	Reliability and validity of the Italian version of the hand functional disability scale in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2008, 27, 743-749.	1.0	20
96	Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (Prognostic Index for) Tj ETQq0 0 0 rgBT6,0verlock10 Tf 50 5	1.0	10
97	Disease-modifying anti-rheumatic drugs (DMARDs) for Sjogren's syndrome. <i>The Cochrane Library</i> , 0, , .	1.5	0